180
Participants
Start Date
July 7, 2021
Primary Completion Date
April 16, 2022
Study Completion Date
April 16, 2022
a2 Platinum® stage 1 infant formula
Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
Conventional, A1 and A2 β-casein containing stage 1 infant formula
Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
Second Hospital of Jilin University, Changchun
Shanghai First Maternity and Infant Hospital, Shanghai
Nanjing Maternity and Child Health Care Hospital, Nanjing
Women & Children's Health Care Hospital of Linyi, China, Linyi
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin
Shanghai First Maternity and Infant Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Edanz Group Japan Ltd
UNKNOWN
Women & Children's Health Care Hospital of Linyi, China
UNKNOWN
Beijing Esmile Technology Co. Ltd.
UNKNOWN
Nanjing Maternity and Child Health Care Hospital
OTHER
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
OTHER
Second Hospital of Jilin University
OTHER
a2 Milk Company Ltd.
INDUSTRY